DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,115 filers reported holding DANAHER CORPORATION in Q3 2017. The put-call ratio across all filers is 0.49 and the average weighting 0.5%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,134,056 | +4.3% | 24,726 | +0.6% | 0.71% | +11.3% |
| Q2 2023 | $5,881,200 | -7.8% | 24,567 | -3.0% | 0.64% | -13.4% |
| Q1 2023 | $6,377,636 | -4.2% | 25,320 | +1.1% | 0.73% | -8.2% |
| Q4 2022 | $6,655,148 | +8.0% | 25,044 | +5.0% | 0.80% | -0.6% |
| Q3 2022 | $6,162,000 | -8.6% | 23,858 | -10.4% | 0.80% | -2.3% |
| Q2 2022 | $6,740,000 | -11.4% | 26,626 | +2.5% | 0.82% | +9.6% |
| Q1 2022 | $7,610,000 | -21.1% | 25,967 | -11.4% | 0.75% | -21.1% |
| Q4 2021 | $9,644,000 | +8.9% | 29,294 | +0.8% | 0.95% | -4.0% |
| Q3 2021 | $8,854,000 | +10.2% | 29,061 | -2.9% | 0.99% | +8.5% |
| Q2 2021 | $8,037,000 | +10.0% | 29,926 | -7.8% | 0.92% | +12.1% |
| Q1 2021 | $7,307,000 | +8.9% | 32,446 | +7.4% | 0.82% | +1.9% |
| Q4 2020 | $6,710,000 | +2.2% | 30,205 | -0.9% | 0.80% | -12.6% |
| Q3 2020 | $6,565,000 | +20.0% | 30,475 | -1.6% | 0.92% | +9.4% |
| Q2 2020 | $5,473,000 | +18.5% | 30,971 | -7.2% | 0.84% | -5.1% |
| Q1 2020 | $4,619,000 | -9.4% | 33,367 | +0.4% | 0.88% | +21.5% |
| Q4 2019 | $5,096,000 | +14.9% | 33,245 | +8.3% | 0.73% | +2.5% |
| Q3 2019 | $4,436,000 | -22.2% | 30,711 | -23.0% | 0.71% | -23.3% |
| Q2 2019 | $5,701,000 | -2.4% | 39,888 | -9.8% | 0.92% | -1.0% |
| Q1 2019 | $5,839,000 | +26.4% | 44,216 | -1.3% | 0.93% | +12.7% |
| Q4 2018 | $4,620,000 | -3.9% | 44,777 | +1.1% | 0.83% | +0.7% |
| Q3 2018 | $4,807,000 | +2.7% | 44,306 | -6.7% | 0.82% | -25.8% |
| Q2 2018 | $4,681,000 | -0.1% | 47,480 | -0.8% | 1.11% | +44.3% |
| Q1 2018 | $4,685,000 | +8.5% | 47,862 | +2.9% | 0.77% | +3.2% |
| Q4 2017 | $4,317,000 | +5.3% | 46,503 | -2.8% | 0.74% | +1.2% |
| Q3 2017 | $4,101,000 | +0.5% | 47,867 | -1.0% | 0.73% | -0.4% |
| Q2 2017 | $4,082,000 | +0.1% | 48,365 | +1.5% | 0.74% | -3.0% |
| Q1 2017 | $4,078,000 | -4.4% | 47,668 | -13.1% | 0.76% | -10.0% |
| Q4 2016 | $4,267,000 | -6.1% | 54,870 | -5.5% | 0.84% | -10.8% |
| Q3 2016 | $4,546,000 | -19.2% | 58,045 | +4.2% | 0.95% | -22.3% |
| Q2 2016 | $5,625,000 | +95.4% | 55,701 | +83.7% | 1.22% | +83.3% |
| Q1 2016 | $2,878,000 | +2.4% | 30,325 | +0.2% | 0.66% | +0.9% |
| Q4 2015 | $2,811,000 | +4.7% | 30,257 | -4.0% | 0.66% | +1.9% |
| Q3 2015 | $2,684,000 | -1.3% | 31,523 | -0.8% | 0.65% | +2.2% |
| Q2 2015 | $2,718,000 | +5.4% | 31,785 | +4.5% | 0.63% | +6.6% |
| Q1 2015 | $2,579,000 | -2.2% | 30,423 | -1.3% | 0.59% | -9.2% |
| Q4 2014 | $2,637,000 | +9.6% | 30,817 | -2.7% | 0.65% | +7.2% |
| Q3 2014 | $2,405,000 | – | 31,669 | – | 0.61% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |